Cohort study of fatty acid synthase expression and patient survival in colon cancer.

PURPOSE Energy balance seems to be important in the pathogenesis of colon cancer. Fatty acid synthase (FASN) is physiologically regulated by energy balance and is often upregulated in colorectal cancer. Nonetheless, the influence of FASN expression on patient outcome is uncertain. PATIENTS AND METHODS Using the database of 647 patients with colon cancer in two independent cohort studies, FASN overexpression was detected in 84 tumors (13%) by immunohistochemistry. Cox proportional hazards models calculated hazard ratios (HRs) of colon cancer-specific and overall mortalities, adjusted for patient characteristics and related tumoral features, including KRAS, BRAF, p53, microsatellite instability and the CpG island methylation phenotype. RESULTS There were 279 deaths, including 160 colon cancer-specific deaths. FASN overexpression was associated with a significant reduction in colon cancer-specific mortality by both univariate and multivariate analyses (adjusted HR, 0.41; 95% CI, 0.19 to 0.89) and an insignificant trend toward improved overall mortality (adjusted HR, 0.75; 95% CI, 0.50 to 1.13). Notably, the effect of FASN expression on mortality might be different according to body mass index (BMI; P(interaction) = .019); the adjusted HR of overall mortality for FASN overexpression was 0.63 (95% CI, 0.39 to 1.02) among patients with BMI less than 27.5 kg/m(2) and 2.91 (95% CI, 1.19 to 7.12) among those with BMI >or= 27.5 kg/m(2). Moreover, the adverse effect of moderate overweight/obesity on overall survival was limited to FASN-positive tumors (adjusted HR, 4.10; 95% CI, 1.14 to 14.8; BMI >or= 27.5 kg/m(2) v < 27.5 kg/m(2)). CONCLUSION Among nonobese patients with colon cancer, tumoral FASN overexpression is associated with improved survival, whereas among moderately overweight or obese patients (BMI >or= 27.5 kg/m(2)), FASN overexpression may predict a worse outcome.

[1]  E. Araki,et al.  AMPK and cell proliferation – AMPK as a therapeutic target for atherosclerosis and cancer , 2006, The Journal of physiology.

[2]  Y. Mo,et al.  Fatty acid synthase gene is up-regulated by hypoxia via activation of Akt and sterol regulatory element binding protein-1. , 2008, Cancer research.

[3]  M. Loda,et al.  Fatty acid synthase overexpression in colorectal cancer is associated with microsatellite instability, independent of CpG island methylator phenotype. , 2007, Human pathology.

[4]  M. Loda,et al.  The isopeptidase USP2a regulates the stability of fatty acid synthase in prostate cancer. , 2004, Cancer cell.

[5]  J. Menéndez,et al.  Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis , 2007, Nature Reviews Cancer.

[6]  Stephan Gripp,et al.  Survival prediction in terminally ill cancer patients by clinical estimates, laboratory tests, and self-rated anxiety and depression. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  M. Loda,et al.  Distinct molecular features of colorectal carcinoma with signet ring cell component and colorectal carcinoma with mucinous component , 2006, Modern Pathology.

[8]  M. Loda,et al.  CpG island methylator phenotype-low (CIMP-low) in colorectal cancer: possible associations with male sex and KRAS mutations. , 2006, The Journal of molecular diagnostics : JMD.

[9]  A. Rashid,et al.  Elevated expression of fatty acid synthase and fatty acid synthetic activity in colorectal neoplasia. , 1997, The American journal of pathology.

[10]  F. Kuhajda,et al.  Fatty acid synthase and cancer: new application of an old pathway. , 2006, Cancer research.

[11]  Shuji Ogino,et al.  Precision and performance characteristics of bisulfite conversion and real-time PCR (MethyLight) for quantitative DNA methylation analysis. , 2006, The Journal of molecular diagnostics : JMD.

[12]  F. Marandino,et al.  Immunohistochemical expression of fatty acid synthase, apoptotic-regulating genes, proliferating factors, and ras protein product in colorectal adenomas, carcinomas, and adjacent nonneoplastic mucosa. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[13]  C. Bogardus,et al.  A novel missense substitution (Val1483Ile) in the fatty acid synthase gene (FAS) is associated with percentage of body fat and substrate oxidation rates in nondiabetic Pima Indians. , 2004, Diabetes.

[14]  M. Gorospe,et al.  Pharmacological inhibition of fatty acid synthase activity produces both cytostatic and cytotoxic effects modulated by p53. , 2001, Cancer research.

[15]  N. Sathiakumar,et al.  Using the National Death Index to obtain underlying cause of death codes. , 1998, Journal of occupational and environmental medicine.

[16]  H. Yatsuya,et al.  A prospective study of body size and colon cancer mortality in Japan: The JACC Study , 2004, International Journal of Obesity.

[17]  P. B. Eveleth,et al.  Physical Status: The Use and Interpretation of Anthropometry. Report of a WHO Expert Committee , 1996 .

[18]  Shuji Ogino,et al.  Aspirin and the risk of colorectal cancer in relation to the expression of COX-2. , 2007, The New England journal of medicine.

[19]  P. Visca,et al.  Expression of fatty acid synthase (FAS) as a predictor of recurrence in stage I breast carcinoma patients , 1996, Cancer.

[20]  R. Houlston,et al.  Systematic review of microsatellite instability and colorectal cancer prognosis. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  P. Laird,et al.  CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer , 2006, Nature Genetics.

[22]  T. Gansler,et al.  Increased expression of fatty acid synthase (OA-519) in ovarian neoplasms predicts shorter survival. , 1997, Human Pathology.

[23]  M. Moroni,et al.  Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  P. Febbo,et al.  Fatty acid synthase expression defines distinct molecular signatures in prostate cancer. , 2003, Molecular cancer research : MCR.

[25]  C. Haiman,et al.  Association of methylenetetrahydrofolate reductase gene polymorphisms and sex-specific survival in patients with metastatic colon cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  J. Nelson,et al.  Increased fatty acid synthase expression and activity during progression of prostate cancer in the TRAMP model , 2003, The Prostate.

[27]  E. Jaffee,et al.  Fatty acid synthase inhibitors are chemopreventive for mammary cancer in neu-N transgenic mice , 2005, Oncogene.

[28]  J. Meyerhardt,et al.  Influence of body mass index on outcomes and treatment‐related toxicity in patients with colon carcinoma , 2003, Cancer.

[29]  S. Kridel,et al.  Fatty acid synthase inhibitors: new directions for oncology , 2007, Expert opinion on investigational drugs.

[30]  Todd Thornburg,et al.  Dietary fat’gene interactions in cancer , 2007, Cancer and Metastasis Reviews.

[31]  E. Rimm,et al.  Validity of Self‐Reported Waist and Hip Circumferences in Men and Women , 1990, Epidemiology.

[32]  Manuel Hidalgo,et al.  Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  M. Loda,et al.  Evaluation of markers for CpG island methylator phenotype (CIMP) in colorectal cancer by a large population-based sample. , 2007, The Journal of molecular diagnostics : JMD.

[34]  M. Loda,et al.  Sensitive sequencing method for KRAS mutation detection by Pyrosequencing. , 2005, The Journal of molecular diagnostics : JMD.

[35]  M. Gunter,et al.  Obesity and colorectal cancer: epidemiology, mechanisms and candidate genes. , 2006, The Journal of nutritional biochemistry.

[36]  S. Ogino,et al.  Molecular classification and correlates in colorectal cancer. , 2008, The Journal of molecular diagnostics : JMD.

[37]  Jeffrey W. Smith,et al.  Orlistat Is a Novel Inhibitor of Fatty Acid Synthase with Antitumor Activity , 2004, Cancer Research.

[38]  D. English,et al.  Effect of physical activity and body size on survival after diagnosis with colorectal cancer , 2005, Gut.

[39]  S Srivastava,et al.  A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. , 1998, Cancer research.

[40]  S. Kridel,et al.  Inhibition of fatty acid synthase induces endoplasmic reticulum stress in tumor cells. , 2007, Cancer research.

[41]  J. Menéndez,et al.  Inhibition of Tumor-associated Fatty Acid Synthase Hyperactivity Induces Synergistic Chemosensitization of HER-2/neu-Overexpressing Human Breast Cancer Cells to Docetaxel (taxotere) , 2004, Breast Cancer Research and Treatment.

[42]  R. Labianca,et al.  Nuclear factor-kB tumor expression predicts response and survival in irinotecan-refractory metastatic colorectal cancer treated with cetuximab-irinotecan therapy. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  N. Wolmark,et al.  Body mass index and outcomes in patients who receive adjuvant chemotherapy for colon cancer. , 2006, Journal of the National Cancer Institute.

[44]  M. Loda,et al.  CpG island methylator phenotype (CIMP) of colorectal cancer is best characterised by quantitative DNA methylation analysis and prospective cohort studies , 2006, Gut.

[45]  M. Loda,et al.  Combined analysis of COX-2 and p53 expressions reveals synergistic inverse correlations with microsatellite instability and CpG island methylator phenotype in colorectal cancer. , 2006, Neoplasia.

[46]  J. C. Barrett,et al.  The utility of genetically altered mouse models for nutrition and cancer chemoprevention research. , 2005, Mutation research.

[47]  Graham A Colditz,et al.  Physical activity and survival after colorectal cancer diagnosis. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[48]  Norman Wolmark,et al.  Prognostic and predictive roles of high-degree microsatellite instability in colon cancer: a National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project Collaborative Study. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[49]  C. Boland Clinical uses of microsatellite instability testing in colorectal cancer: an ongoing challenge. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[50]  Graham A. Colditz,et al.  The Nurses' Health Study: lifestyle and health among women , 2005, Nature Reviews Cancer.